The role of sulfur in platinum anticancer chemotherapy.
Sulfur manifests its influence on platinum anticancer chemotherapy in two aspects: endogenous sulfur-containing molecules such as cysteine, methionine, glutathione, metallothionein and albumin affect the metabolism of platinum drugs and exert adverse effects on the therapeutic efficacy; exogenous congeners such as amifostine (WR-2721) and dimesna (BNP7787) mitigate the toxic side effects of platinum drugs and serve as chemoprotectants. The platinum-sulfur interactions are ubiquitous in the human body and many occurrences encountered during platinum chemotherapy such as uptake, excretion, resistance, and toxicity are related to them. Thus, sulfur-containing molecules play significant roles in the anticancer mechanism of platinum drugs. In this review, the platinum-sulfur interactions are summarized in detail, which may be important for efficient clinical use of the existing platinum agents and beneficial to the rational design of new generation of platinum-based anticancer drugs.
Wang And
Xiaoyong
X
State Key Laboratory of Pharmaceutical Biotechnology, School of Life Science, Nanjing University, 210093, Nanjing, PR China.
Guo
Zijian
Z
D000818:Animals; D000970:Antineoplastic Agents / Q000009:adverse effects / Q000378:metabolism / Q000627:therapeutic use; D004347:Drug Interactions; D019008:Drug Resistance, Neoplasm / Q000187:drug effects; D006801:Humans; D015394:Molecular Structure; D009369:Neoplasms / Q000188:drug therapy* / Q000378:metabolism; D009944:Organoplatinum Compounds / Q000009:adverse effects / Q000378:metabolism / Q000627:therapeutic use; D017671:Platinum Compounds / Q000009:adverse effects / Q000378:metabolism / Q000627:therapeutic use; D013457:Sulfur Compounds / Q000009:adverse effects / Q000378:metabolism / Q000627:therapeutic use
D000970:Antineoplastic Agents; D009944:Organoplatinum Compounds; D017671:Platinum Compounds; D013457:Sulfur Compounds